| Follow us on Twitter |
The OTCFN Report includes details on the ProtoKinetix technology platform, its multiple commercial applications, global target markets and management team.
"Dr. Castelot-Deliencourt, chief scientist for ProtoKinetix, has achieved what was previously thought to be the impossible. She created a synthetic version of AFGP (Anti-Freeze Glycoprotein), a naturally occurring compound that enables cell survival in freezing temperatures. Her lab-created version is the industry's first stable, non-toxic and bioactive compound, even at low concentrations. Patented and trademarked by ProtoKinetix as AAGPs, this revolutionary technology and its derivatives have shown to increase cellular health, survival and seem to have anti-inflammatory properties," said Geoffrey Eiten, publisher of the OTCFN Report.
"This year, ProtoKinetix entered its exciting commercial development phase, establishing partnerships with skin care manufacturers, and umbilical cord blood and health care companies to research and develop life-enhancing applications of AAGP. The Company's goal is to begin generating recurring licensing revenues and royalty fees in 2009, and to increase shareholder value over the long-term," concluded Eiten. -- www.cnxmarketlink.com
Posted October 31st, 2008 by ruzik_tuzik
